Aesica Recruits Technical Director and Two New Business Development Managers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica Recruits Technical Director and Two New Business Development Managers


Aesica, a contract development and manufacturing organization (CDMO), announced that it has appointed Bashir Hansraj as global technical director. Based at Aesica’s Newcastle headquarters in the UK, Hansraj will be responsible for developing global lead technical centers for API development, drug product development and technology innovation. The technical centers will be dedicated to specific dosage forms including oral solids, oral liquids, topicals, inhalation and parenterals.

Hansraj has more than 30 years of experience in the pharmaceutical industry, having held senior management R&D roles within Pfizer Consumer Healthcare, J&J, Pfizer Global R&D and most recently, at Catalent where he was head of R&D. In addition to life science degrees, Hansraj also has an MBA and, in his previous roles, led the development and commercialization of many leading brands utilizing various technology platforms.

Aesica also recently appointed two new business development managers, David Ross and Sven Thomas, as part of the company’s strategic drive to further revenues growth in Europe. Their appointment is the next phase in the company’s strategy to increase sales from its integrated API, formulation development and manufacturing services and they will be responsible for ensuring potential customers are clearly aware of how the company can support their manufacturing and development needs. David Ross will focus on the UK, Ireland and Scandinavia whilst Sven Thomas will handle Central and Eastern Europe with a strong emphasis on expanding the level of business from Germany and the growing economies in Eastern Europe. Ross has experience in contract research and contract manufacturing with Patheon, Catalant and Ipsen, whereas Thomas who previously worked for UCB, brings to the table his breadth of pharmaceutical manufacturing expertise.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here